Evidence map›Paper›PMID 42721975›Full record

ArticleCell reports. Medicine2026

A stem-like chromatin program in small-cell lung cancer is associated with poor outcomes after chemoimmunotherapy.

Rajesh Kumar, Parth Desai, Rajaa El Meskini, Chirayu Mohindroo, Alexandra Ágnes Benő, Devon Atkinson, Michael Nirula, Laura Bassel, Nobuyuki Takahashi, Kelly L Sovacool and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Rajesh KumarDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Parth DesaiDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Rajaa El MeskiniCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Chirayu MohindrooDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Alexandra Ágnes BenőCancer Genomics and Epigenetics Core Group, Hungarian Centre of Excellence for Molecular Medicine, Szeged, Hungary.
Devon AtkinsonCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Michael NirulaDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Laura BasselCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Nobuyuki TakahashiDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Kelly L SovacoolCollaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute/National Institutes of Health, Bethesda, MD, USA; Advanced Biomedical Computational Science, Frederick National Laboratory Research, Frederick, MD, USA.
Anna MeinhardtDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mohit AroraDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kanak ParmarDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Darryl NausomeCollaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute/National Institutes of Health, Bethesda, MD, USA.
Samantha NicholsDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Linda SciutoDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Shannon SwiftThoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Kolos NemesCancer Genomics and Epigenetics Core Group, Hungarian Centre of Excellence for Molecular Medicine, Szeged, Hungary.
Ajit Kumar SharmaDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Nathan PateCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Arun RajanThoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Elliot LevyInterventional Radiology, National Institutes of Health Clinical Center, Bethesda, MD, USA.
Michael KassinInterventional Radiology, National Institutes of Health Clinical Center, Bethesda, MD, USA.
Christopher Febres AldanaLaboratory of Pathology, National Institutes of Health Clinical Center, Bethesda, MD, USA.
Vishal KopardeCollaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute/National Institutes of Health, Bethesda, MD, USA; Advanced Biomedical Computational Science, Frederick National Laboratory Research, Frederick, MD, USA.
Melissa GallouxIndependent Bioinformatician, Marseille, France.
Roshan ShreshtaDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Zoe Weaver OhlerCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Lorinc PongorCancer Genomics and Epigenetics Core Group, Hungarian Centre of Excellence for Molecular Medicine, Szeged, Hungary.
Anish ThomasDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Robert H. Lurie Comprehensive Cancer Center and Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. Electronic address: anish.thomas@northwestern.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small-cell lung cancer (SCLC) is an aggressive malignancy with substantial tumor heterogeneity and limited clinically actionable biomarkers beyond established features such as liver metastases. We profile tumor-intrinsic chromatin accessibility in a patient-derived xenograft biobank and identify three recurrent chromatin programs: neuroendocrine, marked by ASCL1/NEUROD1 activity; immunogenic, marked by IRF-associated activity; and stem-like, marked by TEAD/OCT activity. These programs are reproduced at the cohort level across bulk and single-cell transcriptomic datasets comprising more than 800 tumors, including 300 extensive-stage samples. In patients treated with chemoimmunotherapy, the stem-like program is associated with inferior survival, including a median overall survival of 7.41 months versus 15.9 and 12.6 months for immunogenic and neuroendocrine groups, respectively. This association remains significant after adjustment for liver metastases, brain metastases, and elevated lactate dehydrogenase. These findings support a high-risk stem-like SCLC chromatin program for prospective biomarker refinement and therapeutic investigation.

Indexed as

ChromatinImmunotherapyLung NeoplasmsNeoplastic Stem CellsSmall Cell Lung CarcinomaAnimalsBasic Helix-Loop-Helix ProteinsBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMaleMiceMiddle AgedTreatment OutcomeASCL1 protein, humanBasic Helix-Loop-Helix ProteinsBiomarkers, TumorChromatinATAC-seqbiomarkerchemoimmunotherapychromatin accessibilitymulti-omicsPDXplasticityregulatory programssmall-cell lung cancerstem-like tumor state

Identifiers

PMID42721975
PMCPMC13710148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.